Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models

Anticancer Research

Volumn 29, Issue 6, 2009, Pages 1999-2007

  Tonra, James R ^a,b   Corcoran, Erik ^a   Deevi, Dhanvanthri S ^a   Steiner, Philipp ^a   Kearney, Jessica ^a   Li, Huiling ^a   Ludwig, Dale L ^a   Zhu, Zhenping ^a   Witte, Larry ^a   Surguladze, David ^a   Hicklin, Daniel J ^a  

^a ELI LILLY AND COMPANY   (United States)

^b NONE   (United States)

Author keywords

Combination targeted therapy; EGFR; IGF IR; VEGF; Xenograft

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY DC101; MONOCLONAL ANTIBODY IMC A12; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER MODEL; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; FEMALE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MALE; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS CANCER; PARAAORTIC LYMPH NODE; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT DURATION; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MICE; MICE, NUDE; PANCREATIC NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 67650915107     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Ciardiello F, Bianco R, Damiano V, Fontanini G, Caputo R, Pomatico G, De Placido S, Bianco AR, Mendelsohn J and Tortora G: Antiangiogenic and antitumor activity of antiepidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 6: 3739-3747, 2000. (Pubitemid 30694960)
2. Shaheen RM, Ahmad SA, Liu W, Reinmuth N, Jung YD, Tseng WW, Drazan KE, Bucana CD, Hicklin DJ and Ellis LM: Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Brit J Cancer 85: 584-589, 2001. (Pubitemid 32808285)
3. Tonra JR, Deevi DS, Corcoran E, Li H, Wang S, Carrick FE and Hicklin DJ: Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin Cancer Res 12: 2197-2207, 2006.
4. Lu D, Zhang H, Ludwig D, Persaud A, Jimenez X, Burtrum D, Balderes P, Liu M, Bohlen P, Witte L and Zhu Z: Simultaneous blockade of both epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. J Biol Chem 279: 2856-2865, 2004. (Pubitemid 38114277)
5. Zhang X, Chen ZG, Choe MS, Lin Y, Sun SY, Wieand HS, Shin HJ, Chen A, Khuri FR and Shin DM: Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clin Cancer Res 11: 6261-6269, 2005. (Pubitemid 41262957)
6. Larbouret C, Robert B, Navarro-Teulon I, Thezenas S, Ladjemi MZ, Morisseau S, Campigna E, Bibeau F, Mach JP, Pelegrin A and Azria D: In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clin Cancer Res 13: 3356-3362, 2007.
7. Jimeno A, Kulesza P, Wheelhouse J, Chan A, Zhang X, Kincaid E, Chen R, Clark DP, Forastiere A and Hidalgo M: Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. Br J Cancer 96: 952-959, 2007. (Pubitemid 46452288)
8. Baselga J and Arteaga CL: Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 23: 2445-2459, 2005. (Pubitemid 47050835)
9. Masui H, Kawamoto T, Sato JD, Wolf B, Sato G and Mendelsohn J: Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 44: 1002-1007, 1984. (Pubitemid 14152782)
10. Millauer B, Wizigmann-Voos S, Schnurch H, Martinez R, Moller NP, Risau W and Ullrich A: High affinity VEGF binding and developmental expression suggest Flk-1 as a major regulator of vasculogenesis and angiogenesis. Cell 72: 835-846, 1993. (Pubitemid 23110226)
11. Hicklin DJ and Ellis LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23: 1011-1027, 2005. (Pubitemid 46202320)
12. Shaheen RM, Ahmad SA, Liu W, Reinmuth N, Jung YD, Tseng WW, Drazan KE, Bucana CD, Hicklin DJ and Ellis LM: Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Brit J Cancer 85: 584-589, 2001. (Pubitemid 32808285)
13. Harris A: Hypoxia-A key regulatory factor in tumor growth. Nat Rev Cancer 2: 38-47, 2002. (Pubitemid 37328806)
14. Luwor RB, Lu Y, Li X, Mendelsohn J and Fan Z: The antiepidermal growth factor receptor monoclonal antibody cetuximab/C225 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene 24: 4433-4441, 2005. (Pubitemid 40961766)
15. Casanovas O, Hicklin DJ, Bergers G and Hanahan D: Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8: 299-309, 2005. (Pubitemid 41443415)
16. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Akiyama M, Hideshima T, Chauhan C, Joseph M, Libermann TA, Garcia-Echeverria C, Pearson MA, Hofmann F, Anderson KC and Kung AL: Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 5: 221-230, 2004. (Pubitemid 38402114)
17. Chakravarti A, Loeffler JS and Dyson NJ: Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62: 200-207, 2002. (Pubitemid 34074005)
18. Tsutsumi S, Kuwano H, Morinaga N, Shimura T and Asao T: Animal model of para-aortic lymph node metastasis. Cancer Lett 169: 77-85, 2001. (Pubitemid 32532099)
19. Rowinsky EK, Youssoufian H, Tonra JR, Solomon P, Burtrum D and Ludwig DL: IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 13: 5549s-5555s, 2007. (Pubitemid 47510386)
20. Jenkins DE, Hornig YS, Oei Y, Dusich J and Purchio T: Bioluminescent human breast cancer cell lines that permit rapid and sensitive in vivo detection of mammary tumors and multiple metastases in immune deficient mice. Breast Cancer Res 7: R444-454, 2005.
21. Hansen-Algenstaedt N, Stoll BR, Padera TP, Dolmans DE, Hicklin DJ, Fukumura D and Jain RK: Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy. Cancer Res 60: 4556-4560, 2000. (Pubitemid 32103640)
22. Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J and Kerbel RS: Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Cancer Res 61: 5090-5101, 2001.
23. Vallbohmer D, Zhang W, Gordon M, Yang DY, Yun J, Press OA, Rhodes KE, Sherrod AE, Iqbal S, Danenberg KD, Groshen S and Lenz H-J: Molecular determinants of cetuximab efficacy. J Clin Oncol 23: 3536-3544, 2005.
24. Resnicoff M: Antitumor effects elicited by antisense-mediated down-regulation of the insulin-like growth factor I receptor. Int J Mol Med 1: 883-888, 1998.
25. Kurai J, Chikumi H, Hashimoto K, Yamaguchi K, Yamasaki A, Sako T, Touge H, Makino H, Takata M, Miyata M, Nakainoto M, Burioka N and Shimizu E: Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 13: 1552-1561, 2007. (Pubitemid 46450447)
26. Chu E: Dual biologic therapy in the first-line mCRC setting: implications of the CAIRO2 study. Clin Colorectal Cancer 7: 226, 2008.
27. Bukowski RM, Kabbinavar FF, Figlin RA, Flaherty K, Srinivas S, Vaishampayan U, Drabkin HA, Dutcher J, Ryba S, Xia Q, Scappaticci FA and McDermott D: Randomized Phase II study of Erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 25: 4536-4541, 2007. (Pubitemid 350035309)
28. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK and Sandler A: Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 23: 2544-2555, 2005.
29. Saltz LB, Lenz H-J, Kindler HL, Hochster HS, Wadler S, Hoff PM, Kemeny NE, Hollywood EM, Gonen M, Quinones M, Morse M and Chen HX: Randomized Phase II trial of cetuximab, bevacizumab and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 25: 4557-4561, 2007. (Pubitemid 350035312)
30. Camidge DR, Eckhardt SG, Diab S, Gore L, Chow L, O'Bryant C, Temmer E, Ervin-Haynes A, Katz T, Fox F and Cohen RB: A phase I dose-escalation study of weekly IMC-1121B, a fully human antivascular growth factor receptor 2 (VEGFR2) IgG1 monoclonal antibody (Mab), in patients (pts) with advanced cancer. Proc Am Soc Clin Oncol 24: 3032, 2006.